GHRS News and Press, GH Research PLC From 06/29/23

2023-06-29 12:54:19 ET President Joe Biden is very "open-minded about" psychedelic medications, his youngest brother Frank Biden said during an interview on Wednesday, recalling a conversation the siblings had about the psychoactive substances. "He is very open-minded," the younger Bide...

2023-06-23 13:32:08 ET The U.S. Food and Drug Administration (FDA) published a new draft guidance on investigations into psychedelic drugs on Friday, detailing considerations for their clinical trials for the first time. The recommendations come at a time when there is growing public in...

2023-06-16 11:06:16 ET Summary GH Research PLC is developing mebufotenin, developed from toad venom, as an antidepressant. They have some early positive data. However, toad venom is a controlled substance and will face approval difficulties. GH Research PLC ( G...

2023-05-11 11:44:03 ET GH Research press release ( NASDAQ: GHRS ): Q1 GAAP EPS of -$0.21. Cash, cash equivalents, other financial assets and marketable securities were $246.1 million as of March 31, 2023, compared to cash, cash equivalents and marketable securities of $251...

DUBLIN, Ireland, May 11, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the first quarter ended March 31, 2023 and provided ...

2023-03-24 12:20:59 ET Gainers: Silvergate Capital Corporation ( SI ) +66% . NaaS Technology ( NAAS ) +36% . Assure Holdings ( IONM ) +21% . Dermata Therapeutics ( DRMA ) +21% . ReNew Energy Global ( RNW ) +20% . GH Research ...

2023-03-24 10:01:43 ET Gainers: Dermata Therapeutics ( DRMA ) +40% . GH Research ( GHRS ) +27% . Vaccitech ( VACC ) +25% . Cosmos Health ( COSM ) +10% . Assure ( IONM ) +6% . Losers: BridgeBio Pharma ( BBIO ) -9%...

DUBLIN, Ireland, March 02, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the full year ended December 31, 2022 and gave upd...

Summary Stephen Tobin on investing in psychedelic stocks while they're still pre-revenue. Will first-movers get the advantage? Importance of patents and cash in the industry. Why he's a big believer in Compass and Atai and not as much in Cybin or MindMed. What will move share pr...

Initial approvals received for Phase 2b trial of GH001 in TRD (GH001-TRD-201), initiation of this trial expected in Q1 2023 Development of proprietary aerosol delivery device for GH001 progressed, IND submission with this device expected in Q3 2023 Phase 1 trial of GH002 in healthy volunt...